ClinicalTrials.gg
Not yet recruitingNCT07301099PLENITUDEUpdated Jan 15, 2026

Epidemiology and Current Practices in Severe Community-Acquired Pneumonia

An observational study in Severe Community-acquired Pneumonia (sCAP), sponsored by Universidad de la Sabana. Not yet recruiting at 1 site in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Universidad de la Sabana · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,588
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn more about severe community-acquired pneumonia (sCAP) in adults who need hospital or intensive care. This type of pneumonia starts outside the hospital and can quickly become life-threatening. The study aims to understand how people with sCAP are cared for in different parts of the world and how these differences relate to their recovery.

  • The main questions this study aims to answer are:
  • What are the characteristics, treatments, and outcomes of adults with sCAP?
  • How closely do hospitals follow international guidelines for diagnosing and treating sCAP?
  • What factors are linked to worse outcomes, such as the need for a ventilator or risk of death?

This study will not test any new drugs or procedures. Instead, researchers will observe the care that participants already receive as part of their normal treatment. Hospitals in many countries will take part, including centres in Europe, North America, Latin America, Asia, Africa, and Oceania. This global participation will help show how sCAP affects people in different health systems and communities.

Participants will be adults who arrive at a hospital or intensive care unit with severe pneumonia. Most information will come from medical records, such as symptoms, test results, treatments given, and how participants respond to care. In some hospitals with special laboratory capacity, additional blood or breathing samples may be collected to study how the body fights infection.

No extra visits are required for routine data-only participants. In sites that collect samples, these will usually be taken at the same time as routine medical care to avoid extra procedures. Researchers will also ask about recovery after hospital discharge at 60 days, 6 months, and 12 months. These follow-ups will help us understand long-term health, complications, and quality of life after sCAP.

By collecting information from a large number of hospitals around the world, this study hopes to identify patterns that can help improve diagnosis, treatment, and survival for people with severe pneumonia. The findings may also help health care teams and public health leaders update treatment guidelines and strengthen care for future patients.

Read the detailed description

Severe community-acquired pneumonia (sCAP) is a life-threatening infection requiring hospital or ICU care. Mortality remains high, and there are major differences worldwide in diagnosis, treatment practices, and availability of resources. Although new international guidelines exist, real-world implementation is not well understood. The PLENITUDE study is a multinational, prospective observational cohort designed to describe global practices, outcomes, microbiology, and biological responses in adults with sCAP using a harmonized research framework.

The study uses a tiered approach aligned with the ISARIC/WHO Clinical Characterisation Protocol. Tier 0 sites collect standardized clinical data from routine medical records. Tier 1 sites also collect a single set of biological samples at admission. Tier 2 sites perform serial biological sampling to evaluate pathogen dynamics and host immune responses over time. This structure allows participation from hospitals with varying levels of resources while preserving core standardization.

Data are collected using variables derived from the ISARIC ARC library to ensure consistency across regions. Clinical information includes demographics, comorbidities, illness severity, laboratory and imaging results, respiratory support, microbiology, treatments, complications, and outcomes. All data are entered into a secure REDCap platform with automated validation rules, range checks, and logic checks. Participant confidentiality is maintained through unique study identifiers and restricted access for authorized personnel.

Quality assurance procedures include programmed data validation, periodic monitoring of completeness and protocol adherence, and selective source data verification. Standard Operating Procedures guide patient identification, sample handling, data entry, and reporting of deviations. Site teams receive training in protocol operations and data management.

Tier 1 and Tier 2 samples follow standardized processing steps based on the ISARIC/WHO CCP, including centrifugation, aliquoting, freezing, and safe handling according to biosafety requirements. Regional laboratory hubs support advanced analyses such as molecular pathogen detection, sequencing, and immune response profiling, improving comparability and quality control across participating countries.

The statistical analysis plan includes descriptive summaries of clinical presentation and management, comparative analyses across regions or guideline adherence groups, multivariable models for risk factor identification, time-to-event analyses, and mixed-effects models for repeated measures in Tier 2. Unsupervised clustering will be used to explore phenotypes and endotypes. Missing data will be addressed using multiple imputation and sensitivity analyses.

Participants are followed during hospitalization and after discharge at 60 days, 6 months, and 12 months to evaluate long-term outcomes, readmissions, persistent symptoms, and quality of life. Follow-up methods include record review and phone or electronic assessments, depending on site capability.

The study is overseen by international Principal Investigators, a Steering Committee of experts, and a centralized data management team. PLENITUDE is expected to generate real-world evidence on global sCAP management, guideline adherence, microbial and immune patterns, and long-term outcomes. These findings may inform improvements in clinical care, strengthen public health strategies, and support future advances in precision medicine for severe pneumonia.

02

Conditions studied

  • Severe Community-acquired Pneumonia (sCAP)

Keywords

  • Pneumonia
  • Respiratory Tract Infections
  • Community-Acquired Pneumonia
  • Respiratory Tract Diseases
03

In context

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

This study's planned enrollment of 2,588 is above the median of 650 across 111 observational studies indexed under Community-Acquired Pneumonia.

Browse Community-Acquired Pneumonia studies →

Lead sponsor

Universidad de la Sabana is the lead sponsor of 23 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enrol adult patients presenting with severe community-acquired pneumonia (sCAP) at participating hospitals and intensive care units worldwide. Participants will be identified through routine clinical care upon hospital or ICU admission. The study includes centres across Europe, North America, Latin America, Asia, Africa, and Oceania, ensuring broad geographical and healthcare system representation. Data-only participants will be sourced from electronic medical records, while biological samples will be collected in Tier 1 and Tier 2 sites with laboratory capacity. The multinational design allows inclusion of patients from high-, middle-, and low-income countries, supporting a diverse and globally representative cohort.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older are hospitalised with a clinical diagnosis of sCAP according to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria.16
  • Admission to participating hospitals or ICUs during the study period.
  • Provision of by the patient or legally authorised representative for those centres collecting biological samples. Data-only participants will not be required to sign informed consent.

Exclusion criteria

Exclusion Criteria:

  • Paediatric population (\<18 years old)
  • Pneumonia acquired in the hospital setting (i.e., nosocomial or hospital-acquired pneumonia).
  • Insufficient clinical information to confirm the diagnosis of sCAP.
  • : i.e. Active cancer, hematopoietic cell transplant, solid organ transplant recipients, diagnosed patients regardless of , chronic immunosuppression with , inborn errors of immunity.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,588 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Adult patients with Severe Community-Acquired Pneumonia (sCAP)

    Clinical follow-up for 12 months

06

What researchers measure

Primary outcomes

  1. All-Cause In-Hospital Mortality

    Proportion of enrolled adult patients with severe community-acquired pneumonia (sCAP) who die from any cause during the index hospitalisation. Mortality status will be abstracted from clinical and administrative records at ICU and hospital discharge. This measure describes the severity and outcomes of sCAP across diverse international healthcare settings.

    Time frame: From hospital admission to hospital discharge (up to 30 days)

  2. Adherence to International sCAP Management Guidelines

    Percentage of adherence to the ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Adherence will be quantified using predefined key indicators related to diagnostic evaluation, antibiotic initiation, ventilatory support, biomarker use, ICU management and follow-up practices. This measure evaluates real-world implementation of guideline-based care across participating centres.

    Time frame: During the index hospitalisation (up to 30 days)

Secondary outcomes

  1. ICU Mortality

    Proportion of patients with sCAP who die during the ICU stay. Mortality status will be obtained from clinical and administrative records. This outcome allows comparison of mortality patterns across regions and centres and contributes to understanding the severity and progression of sCAP within critical care settings.

    Time frame: From ICU admission to ICU discharge (up to 30 days)

  2. 60-Day and 180-Day Mortality

    Proportion of enrolled patients who die within 60 and 180 days after hospital admission. Mortality will be assessed through clinical records, follow-up contacts, and post-discharge documentation. This outcome characterises mid- and long-term survival trajectories in patients who experience sCAP.

    Time frame: 60 days and 180 days after enrolment

  3. Length of Hospital Stay

    Number of days from hospital admission to discharge or death. This measure reflects clinical severity, resource utilisation, and recovery trajectory across diverse healthcare settings.

    Time frame: From hospital admission to discharge (up to 30 days)

  4. Duration of Mechanical Ventilation

    Total duration (in days) of invasive or non-invasive mechanical ventilation among patients requiring respiratory support. This outcome provides insight into respiratory failure severity and treatment practices across participating ICUs.

    Time frame: During the index hospitalisation (up to 30 days)

  5. Occurrence of Major Complications

    Proportion of patients experiencing complications such as septic shock, ARDS, secondary infections, or multi-organ failure during hospitalisation. Complications will be identified using predefined clinical criteria abstracted from medical records.

    Time frame: During the index hospitalisation (up to 30 days)

  6. ICU or Hospital Readmission

    Proportion of patients readmitted to the ICU or hospital within 60 or 180 days after discharge. Readmissions will be assessed through clinical documentation, follow-up visits, and contact with participants or family members.

    Time frame: 60 days and 180 days after discharge

  7. Health-Related Quality of Life (HRQoL)

    Assessment of Health-Related Quality of Life (HRQoL) using the validated EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) at the day of hospital discharge and during follow-up evaluation at 12 months post-discharge. This outcome aims to quantify long-term functional recovery and wellbeing after severe community-acquired pneumonia (sCAP).

    Time frame: At hospital discharge (assessed up to 90 days from admission), and at 12 months (±30 days) following hospital discharge.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — The decision regarding the sharing of individual participant data has not yet been finalized. IPD availability will depend on ethical approvals, institutional policies, and data-governance requirements across participating sites.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.

Of 38 observational studies under Community-Acquired Pneumonia, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 24, 2025
StartEst.
Feb 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Aug 31, 2027
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07301099
Lead sponsor
Universidad de la Sabana
Collaborators
International Severe Acute Respiratory and Emerging Infection Consortium, European Society of Intensive Care Medicine, Latin American Intensive Care Network (LIVEN)
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Feb 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jan 15, 2026

Study contacts

Luis Felipe Reyes, MD, MSc, PhD
Contact
luis.reyes5@unisabana.edu.co
+57 3175130128
Lina Martinez-L, MD
Contact
linamarle@unisabana.edu.co
+57 3015375128
Luis Felipe Reyes, MD, MSc, PhD
principal investigator · Universidad de la Sabana
Ignacio-Martin Loeches, MD, PhD, FJFICMI
principal investigator · St James's Hospital, Trinity College Dublin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion